Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Details Narrative)

v3.22.1
Stockholders’ Equity (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Jan. 25, 2021
Aug. 19, 2020
Oct. 10, 2019
Apr. 30, 2021
Apr. 30, 2022
Apr. 30, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Sale of stock 7,711,284 4,608,589        
Shares price, per share $ 5.45 $ 3.25        
Gross proceeds $ 42,000,000.0 $ 15,000,000.0        
Net proceeds $ 39,100,000 $ 13,500,000        
Cash fees percentage 6.00% 8.00%        
Other expenses $ 400,000 $ 300,000        
Proceeds from stock options exercised         $ 202,800 $ 489,580
Proceeds from warrants exercised         4,792,951
Stock Issued During Period, Value, New Issues           $ 13,513,638
Purchases Agreement Axis [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock Issued During Period, Value, New Issues     $ 28,000,000.0      
China Grand Pharmaceutical and Health Care Holdings Limited [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Sale of stock     1,409,838      
Stock Issued During Period, Value, New Issues     $ 4,800,000      
Share Price     $ 3.45      
China Grand Pharmaceutical and Health Care Holdings Limited [Member] | Purchases Agreement Axis [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Sale of stock     10,000,000      
Sirtex [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Sale of stock     281,968      
Stock Issued During Period, Value, New Issues     $ 1,000,000.0      
Share Price     $ 3.45      
Sirtex [Member] | Purchases Agreement Axis [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Sale of stock     2,000,000      
China Grand Pharmaceutical and Health Care Holdings Limited Sirtex [Member] | Purchases Agreement Axis [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock Issued During Period, Value, New Issues     $ 30,000,000.0      
Common Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Sale of stock           4,608,589
Stock issued during period shares stock options exercised       136,636 130,000 294,884
Proceeds from stock options exercised         $ 200,000 $ 500,000
Stock issued during period shares warrants exercised       507,000   1,389,261
Proceeds from warrants exercised         $ 4,800,000  
Stock Issued During Period, Value, New Issues           $ 461
Warrant [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Stock issued during period shares warrants exercised       (507,000)   (1,389,261)
Number of warrant to purchase shares of common stock         1,706,190  
Stock Issued During Period, Value, New Issues          
Warrant [Member] | Minimum [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Warrant exercise price per share         $ 3.45  
Warrant [Member] | Maximum [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Warrant exercise price per share         $ 16.80